ARPINO, GRAZIA
ARPINO, GRAZIA
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
2005 Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, R. M.
Potent inhibition of EGFR(ErbB1)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu Over-expressing breast tumor xenografts.
2006 M. F., Rimawi; H. L., Weiss; Arpino, Grazia; G. S., Morris; R. D., Soliz; R. M., Ward; T. M., Gilmer; C. K., Osborne; R., Schiff
Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition.
2004 Arpino, Grazia; Weiss, H; Wakeling, Ae; Osborne, K; Schiff, R.
GMO-Gestione Malattie Oncologiche in Regione Campania.
2011 Arpino, Grazia; Cammarota, Simona; DE ANGELIS, Carmine; Pizzi, Claudia; Perone, Vincenzo; Tommasielli, Giuseppina; Arpino, Giovanni; Novellino, Ettore; DE PLACIDO, Sabino
A Metanalysis on the Interaction between HER2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer
2005 DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, E; Ruggiero, A; Carlomagno, Chiara; Ciardiello, F; Tortora, G; D’Agostino, D; Caputo, F; Cancello, G; Montagna, E; Malorni, L; Zinno, L; Lauria, R; Bianco, Ar; DE PLACIDO, Sabino
A Feasibilty Study of a Sequential Dose-Dense Adjuvant Regimen with Epidoxorubicin Followed by Docetaxel Followed by High-Dose Cyclophosphamide for Early Breast Cancer with 4 or More Lymph Node Metastases.
2001 Francesco, Cognetti; Arpino, Grazia; DE LAURENTIIS, Michelino; Paola, Papaldo; Chiara, Sguotti; Modesto, D'Aprile; Francesco, Recchia; DE PLACIDO, Sabino; Angelo Raffaele, Bianco
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
2003 Valerie Jeanne, Bardou; Arpino, Grazia; Richard M., Elledge; C., Kent Osborne; Gary M., Clark
Premalignant and in situ breast disease: biology and clinical implications.
2005 Arpino, Grazia; Rodolfo, Laucirica; Richard M., Elledge
Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
2005 Arpino, Grazia; D. R., Ciocca; H., Weiss; D. C., Allred; P., Daguerre; L., Vargas Roig; M., Leuzzi; F., Gago; R., Elledge; S. K., Mohsin
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
2005 Arpino, Grazia; H. L., Weiss; G. M., Clark; S. G., Hilsenbeck; C. K., Osborne
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
2008 Arpino, Grazia; Lisa, Wiechmann; C., Kent Osborne; Rachel, Schiff
Clinical and biologic features of ER- PR- HER-2- breast cancer compared to estrogen or HER-2 driven phenotypes
2005 Arpino, Grazia; H., Weiss; R., Elledge
Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) on core needle biopsy (CNB) — Clinical significance
2003 Arpino, Grazia; C., Allred; S., Mohsin; H., Weiss; D., Conrow; R., Elledge
Triple-negative breast cancers: Biomarkers and outcomes
2010 Malorni, L.; Shetty, P. B.; Hilsenbeck, S. G.; Rimawi, M. F.; Elledge, R. M.; De Angelis, C.; Osborne, C. K.; DE PLACIDO, Sabino; Arpino, Grazia
HER-2 amplification, EGFR expression, and tamoxifen response in ER-positive metastatic breast cancer; a SWOG study
2002 Arpino, Grazia; S., Green; Dc, Allred; P., Ravdin; D., Lew; S., Martino; Ck, Osborne; R., Elledge
Health-care costs associated with breast cancer management
2010 Cammarota, S.; Citarella, A.; Menditto, Enrica; Putignano, D.; Riegler, S.; De Luca, L.; Malorni, L.; DE PLACIDO, Sabino; Arpino, Grazia
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies
2002 DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; A., Ruggiero; Carlomagno, Chiara; G., Tortora; F., Ciardiello; Ar, Bianco
Predictive value of apoptosis, proliferation, and HER-2 for anthracycline chemotherapy in patients with locally advanced breast cancer
2003 Arpino, Grazia; D. R., Ciocca; H., Weiss; P., Daguerre; L., Vargas Roig; M., Leuzzi; F., Gago; R., Elledge; S., Mohsin
Estrogen receptor-positive, progesterone receptor-negative breast cancer: correlation with growth factor receptor expression and tamoxifen resistance.
2004 Arpino, Grazia; Weiss, H; Lee, A; Schiff, R; Osborne, Ck; Elledge, Rm
Prognostic and predictive factors in breast cancer, an evidence-based medicine approach
2002 Mohsin, Sk; Bardou, Vj; Arpino, Grazia; Chamness, Gc; Allred, Dc
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. | 1.1 Articolo in rivista | 2005 | Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, R. M. | |
| Potent inhibition of EGFR(ErbB1)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu Over-expressing breast tumor xenografts. | 4.1 Articoli in Atti di convegno | 2006 | M. F., Rimawi; H. L., Weiss; Arpino, Grazia; G. S., Morris; R. D., Soliz; R. M., Ward; T. M., Gilmer; C. K., Osborne; R., Schiff | |
| Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition. | 4.1 Articoli in Atti di convegno | 2004 | Arpino, Grazia; Weiss, H; Wakeling, Ae; Osborne, K; Schiff, R. | |
| GMO-Gestione Malattie Oncologiche in Regione Campania. | 2.1 Contributo in volume (Capitolo o Saggio) | 2011 | Arpino, Grazia; Cammarota, Simona; DE ANGELIS, Carmine; Pizzi, Claudia; Perone, Vincenzo; Tommasielli, Giuseppina; Arpino, Giovanni; Novellino, Ettore; DE PLACIDO, Sabino | |
| A Metanalysis on the Interaction between HER2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer | 1.1 Articolo in rivista | 2005 | DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, E; Ruggiero, A; Carlomagno, Chiara; Ciardiello, F; Tortora, G; D’Agostino, D; Caputo, F; Cancello, G; Montagna, E; Malorni, L; Zinno, L; Lauria, R; Bianco, Ar; DE PLACIDO, Sabino | |
| A Feasibilty Study of a Sequential Dose-Dense Adjuvant Regimen with Epidoxorubicin Followed by Docetaxel Followed by High-Dose Cyclophosphamide for Early Breast Cancer with 4 or More Lymph Node Metastases. | 4.1 Articoli in Atti di convegno | 2001 | Francesco, Cognetti; Arpino, Grazia; DE LAURENTIIS, Michelino; Paola, Papaldo; Chiara, Sguotti; Modesto, D'Aprile; Francesco, Recchia; DE PLACIDO, Sabino; Angelo Raffaele, Bianco | |
| Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. | 1.1 Articolo in rivista | 2003 | Valerie Jeanne, Bardou; Arpino, Grazia; Richard M., Elledge; C., Kent Osborne; Gary M., Clark | |
| Premalignant and in situ breast disease: biology and clinical implications. | 1.1 Articolo in rivista | 2005 | Arpino, Grazia; Rodolfo, Laucirica; Richard M., Elledge | |
| Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer. | 1.1 Articolo in rivista | 2005 | Arpino, Grazia; D. R., Ciocca; H., Weiss; D. C., Allred; P., Daguerre; L., Vargas Roig; M., Leuzzi; F., Gago; R., Elledge; S. K., Mohsin | |
| Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. | 1.1 Articolo in rivista | 2005 | Arpino, Grazia; H. L., Weiss; G. M., Clark; S. G., Hilsenbeck; C. K., Osborne | |
| Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. | 1.1 Articolo in rivista | 2008 | Arpino, Grazia; Lisa, Wiechmann; C., Kent Osborne; Rachel, Schiff | |
| Clinical and biologic features of ER- PR- HER-2- breast cancer compared to estrogen or HER-2 driven phenotypes | 4.1 Articoli in Atti di convegno | 2005 | Arpino, Grazia; H., Weiss; R., Elledge | |
| Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) on core needle biopsy (CNB) — Clinical significance | 4.1 Articoli in Atti di convegno | 2003 | Arpino, Grazia; C., Allred; S., Mohsin; H., Weiss; D., Conrow; R., Elledge | |
| Triple-negative breast cancers: Biomarkers and outcomes | 4.1 Articoli in Atti di convegno | 2010 | Malorni, L.; Shetty, P. B.; Hilsenbeck, S. G.; Rimawi, M. F.; Elledge, R. M.; De Angelis, C.; Osborne, C. K.; DE PLACIDO, Sabino; Arpino, Grazia | |
| HER-2 amplification, EGFR expression, and tamoxifen response in ER-positive metastatic breast cancer; a SWOG study | 4.1 Articoli in Atti di convegno | 2002 | Arpino, Grazia; S., Green; Dc, Allred; P., Ravdin; D., Lew; S., Martino; Ck, Osborne; R., Elledge | |
| Health-care costs associated with breast cancer management | 1.5 Abstract in rivista | 2010 | Cammarota, S.; Citarella, A.; Menditto, Enrica; Putignano, D.; Riegler, S.; De Luca, L.; Malorni, L.; DE PLACIDO, Sabino; Arpino, Grazia | |
| HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies | 1.5 Abstract in rivista | 2002 | DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; A., Ruggiero; Carlomagno, Chiara; G., Tortora; F., Ciardiello; Ar, Bianco | |
| Predictive value of apoptosis, proliferation, and HER-2 for anthracycline chemotherapy in patients with locally advanced breast cancer | 4.1 Articoli in Atti di convegno | 2003 | Arpino, Grazia; D. R., Ciocca; H., Weiss; P., Daguerre; L., Vargas Roig; M., Leuzzi; F., Gago; R., Elledge; S., Mohsin | |
| Estrogen receptor-positive, progesterone receptor-negative breast cancer: correlation with growth factor receptor expression and tamoxifen resistance. | 4.1 Articoli in Atti di convegno | 2004 | Arpino, Grazia; Weiss, H; Lee, A; Schiff, R; Osborne, Ck; Elledge, Rm | |
| Prognostic and predictive factors in breast cancer, an evidence-based medicine approach | 2.1 Contributo in volume (Capitolo o Saggio) | 2002 | Mohsin, Sk; Bardou, Vj; Arpino, Grazia; Chamness, Gc; Allred, Dc |